Drs. Kenneth S. Kornman and Lynn Doucette-Stamm of Interleukin Genetics Honored at the 100th Anniversary of the AAP
Interleukin Genetics, Inc. is pleased to share that Dr. Kenneth S. Kornman, Chief Executive Officer and Dr. Lynn Doucette-Stamm, Vice President of Development and Clinical Operations, together with their co-authors, received the Clinical Research Award for a study titled “Patient Stratification for Preventive Care in Dentistry,” which featured the Company’s lead marketed molecular diagnostic product, PerioPredict™.
The award, which recognizes a published scientific manuscript with direct clinical relevance to periodontics, was presented at the 100th American Academy of Periodontology (AAP) Annual Meeting and Anniversary Celebration, held September 19-22, 2014, in San Francisco.
The article, originally published in the Journal of Dental Research (June 2013), outlines the results from a landmark research study supporting Interleukin’s PerioPredict™ genetic test for periodontal disease. The study provided important new insights into the prevention of periodontal disease and the significant opportunity to improve oral health through a personalized approach to preventive care.
In addition, Dr. Kornman discussed the future of periodontology in the AAP 100th Anniversary Opening General Session titled “Pillars of the Past, Foundation for the Future,” that took place on Saturday, September 20, and at an AAP course titled “The Role of Emerging Diagnostics in Periodontal Practice,” that took place on Sunday, September 21.
“Lynn and I are honored to be recognized by the AAP and I am pleased to have been selected to participate in these various events,” said Dr. Kornman. “The concept of personalized medicine is not new, but our current tools, especially in genomics, now allow us to identify and stratify patients with greater precision. I look forward to furthering the personalized medicine discussion and raising awareness about its potential to increasingly shift healthcare from repair to prevention, to select more optimal preventive and therapeutic approaches, to improve quality of life, and to help control the ever-increasing cost of healthcare.”
The PerioPredict™ genetic test is quick, easy and painless and is performed by dentists during a routine exam or cleaning. PerioPredict™ measures variations in genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. The PerioPredict™ test results provide essential information to the dental professional for assessing prevention and treatment options for their patients. PerioPredict™ is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, MA.
For more information, visit www.PerioPredict.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PerioPredict™ genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).
For more information, please visit www.ilgenetics.com.